Mitsubishi Tanabe Pharma America, Inc.
525 Washington Blvd., Suite 400
Jersey City, NJ 07310
TEL 908-607-3010 FAX 201-610-1293

June 8th, 2021
Vermont Attorney General's Office
Via Email (AGO.highcostprescriptiondrugs@vermont.gov)

RE: New Prescription Drug – 30 Day Report

In accordance with 18 V.S.A. § 4637, Mitsubishi Tanabe Pharma America, Inc. (MTPA) is reporting information regarding the commercial introduction of the following new NDC at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program. Per 18 V.S.A. § 4637(d), MTPA has limited the information reported to that which is otherwise in the public domain or publicly available.

NDC	PRODUCT
70510-2201-02	Exservan (riluzole) oral film, 50 mg

(1) A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally:

This information is not otherwise in the public domain or publicly available.

(2) The estimated volume of patients who may be prescribed the drug:

This information is not otherwise in the public domain or publicly available.

(3) Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval:

The drug was not granted breakthrough therapy designation or priority review by the FDA prior to final approval.

(4) The date and price of acquisition if the drug was not developed by the manufacturer:

January 21, 2021

Please do not hesitate to contact us if you have any questions.

Best Regards,

Ekaterina Miteiko
Associate Director, Financial Planning & Analytics, Operations & Strategy
Mitsubishi Tanabe Pharma America, Inc.
525 Washington Blvd. Ste 2620
Jersey City, NJ 07310
Ekaterina_Miteiko@mt-pharma-us.com
Office: 908-607-3061 | Cell: 908-797-1126